Deborah Butler, PharmD

VP & Head of Emerging Markets Regulatory Affairs at GSK
GSK, United Kingdom

Disclosure(s): No financial relationships to disclose

Poster(s):

• 641 - Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019-2020)
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 1675 - Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET